Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Castle Biosciences Inc before investing.

In this article, we go over a few key elements for understanding Castle Biosciences Inc’s stock price such as:

• Castle Biosciences Inc’s current stock price and volume
• Why Castle Biosciences Inc’s stock price changed recently
• Upgrades and downgrades for CSTL from analysts
• CSTL’s stock price momentum as measured by its relative strength

About Castle Biosciences Inc (CSTL)

Before we jump into Castle Biosciences Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.

Want to learn more about Castle Biosciences Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Castle Biosciences Inc.

Castle Biosciences Inc’s Stock Price as of Market Close

As of September 11, 2024, 4:00 PM, CST, Castle Biosciences Inc’s stock price was $31.03.

Castle Biosciences Inc is up 5.9% from its previous closing price of $29.30.

During the last market session, Castle Biosciences Inc’s stock traded between $28.56 and $29.52. Currently, there are 27.65 million shares of Castle Biosciences Inc stock available for purchase.

Unfortunately, Castle Biosciences Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Castle Biosciences Inc Stock Price History

Castle Biosciences Inc’s (CSTL) price is currently up 4.58% so far this month.

During the month of September, Castle Biosciences Inc’s stock price has reached a high of $31.16 and a low of $28.40.

Over the last year, Castle Biosciences Inc has hit prices as high as $30.50 and as low as $12.07. Year to date, Castle Biosciences Inc’s stock is up 31.82%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Castle Biosciences Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 10, 2024, there were 0 analysts who downgraded Castle Biosciences Inc’s stock and 6 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Castle Biosciences Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Castle Biosciences Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Castle Biosciences Inc’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Castle Biosciences Inc (CSTL) by visiting AAII Stock Evaluator.

Relative Price Strength of Castle Biosciences Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 10, 2024, Castle Biosciences Inc has a weighted four-quarter relative price strength of 12.49%, which translates to a Momentum Score of 90 and is considered to be Very Strong.

Want to learn more about how Castle Biosciences Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Castle Biosciences Inc Stock Price: Bottom Line

As of September 11, 2024, Castle Biosciences Inc’s stock price is $31.03, which is up 5.9% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Castle Biosciences Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.